Key Insights

Highlights

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05675436Active Not Recruiting

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Showing all 1 trials

Research Network

Active Sponsors

  • National Heart, Lung, and Blood Institute (NHLBI)1

Top Investigators

Related Conditions

  • Sickle Cell Pain1
  • Hbss1
  • Sickle Beta Thalassemia1
  • Sickle Cell Anemia1
  • Sickle Beta Zero Thalassemia1

Activity Timeline